Pharmafile Logo
Pharmafocus logo
Advanced Search

Allergan

Showing 15 posts of 142 posts found.

allergan

FDA advisory committee approves of Allergan’s night-time urination medicine

October 20, 2016
Medical Communications Allergan, FDA, Night-time urination, sleep, urination

The FDA’s advisory committee ruled, in a 14-4 vote, that Allergan’s experimental nocturnal urination medication, SER120, in favour of the …

News
paul_navarre

Nestlé appoints Paul Navarre as CEO of Nestlé Skin Health

October 12, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Nestle skin health, Paul Navarre, nestle

The announcement of Paul Navarre’s appointed as CEO of Nestlé Skin Health was announced on 11 October. He will take …

Appointment
sicorbio

Teva to sell Allergan’s UK & Ireland generics business for $770m

October 6, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva

Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.

News
medimmune

AstraZeneca agrees $250 million licensing agreement with Allergan

October 3, 2016
Sales and Marketing Allergan, AstraZeneca, Crohn’s disease, MEDI2070, MedImmune, crohn's disease

Allergan has entered into a licensing agreement with MedImmune, of AstraZeneca, for the global rights of MedI2070, a synthetic antibody. …

News
allergan

Allergan expands NASH portfolio with $1.7 billion in acquisitions

September 21, 2016
Research and Development, Sales and Marketing Akarna Therapeutics, Allergan, Tobira Therapeutics, acqusition, nash

Allergan has gone on a spending spree this week, snapping up clinical-stage biotech Tobira Therapeutics and privately-held Akarna Therapeutics for …

News
allergan

Allergan snaps up Vitae Pharma for $639 million

September 15, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Vitae, acquisition

Allergan has agreed to buy clinical-stage biotech Vitae Pharmaceuticals for $639 million, or $21 a share – more than double …

News
brent_saunders

Allergan CEO outlines ‘social contract with patients’

September 7, 2016
Research and Development, Sales and Marketing Allergan, Brent Saunders, CEO, blog

Highlighting a recent shift in the priorities of the pharmaceutical industry, Allergan CEO and president Brent Saunders has outlined a …

News
allergan

Allergan acquires biotech Retrosense for $60 million

September 7, 2016
Research and Development, Sales and Marketing Allergan, Retrosense, acquisition

Allergan has announced that it has acquired Retrosense, a biotech focused on novel gene therapy approaches to restore vision in …

News
allergan

Allergan set to acquire eye-care biotech ForSight VISION5

August 12, 2016
Medical Communications, Sales and Marketing Allergan, ForSight VISION5, acquisition, biotech, eye care

Allergan has announced its acquisition of privately-held, clinical-stage eye-care biotech ForSight VISION5 for a $95 million upfront payment and a …

News
biogen_austria_238

Takeover rumours send Biogen’s stock soaring

August 3, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Biogen, MSD, rumours, takeover

Rumours have begun to circulate that companies including MSD and Allergan are plotting a takeover bid for Biogen, after a …

News
teva_copy

Teva completes $40 billion acquisition of Actavis Generics

August 3, 2016
Research and Development, Sales and Marketing Actavis, Allergan, Teva, acqusition, generics

Teva has announced that it has completed its acquisition of Actavis Generics, a subsidiary of Allergan, in a transaction valued …

News
allergan

IBS-D treatment Truberzi receives positive opinion from CHMP

July 26, 2016
Manufacturing and Production, Sales and Marketing Allergan, EU, Truberzi, diarrhoea. CHMP, irritable bowel syndrome

Global pharmaceutical company Allergan has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of …

News
clinical_trial_4

Phase III study confirms similarity of Herceptin biosimilar from Amgen, Allergan

July 22, 2016
Medical Communications, Research and Development Allergan, Amgen, Herceptin, Roche, biosimilar, trastuzumab

Amgen and Allergan have announced the results from a Phase III study investigating ABP 980, their biosimilar candidate for Roche’s …

News
teva_copy

Teva sells $15 billion in bonds to fund Allergan generics deal

July 19, 2016
Manufacturing and Production, Sales and Marketing Allergan, Teva, bonds, generics

Teva Pharmaceuticals has announced that it has successfully finalised a bond sale totalling $15 billion that will help to fund …

News
teva_copy

Teva looking at up to $25 billion in bond sale to fund Allergan’s generic-unit buy – reports

July 15, 2016
Medical Communications, Sales and Marketing Allergan, Financial, Teva, US regulators, bond sale, deal

Israeli drug firm Teva (NYSE: TEVA) is looking at a $20 billion to $25 billion bond sale in the US …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023